25 May 2013
Keywords: ph, iii, ofatumumab, trial, nhl, completes, recruitment
Article | 20 October 2008
Danish biotechnology firm Genmab AS has completed recruitment of patients in the pivotal Phase III trial of ofatumumab (HuMax-CD20) in
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 October 2008
24 May 2013
© 2013 thepharmaletter.com